Study finds varying survival rates for rare bleeding disorders

A recent study assessing the survival rates of patients with rare bleeding disorders (RBDs) over a 5-year follow-up period found varying rates of survival and suggests the potential benefits of identifying high-risk individuals to improve their survival through timely therapeutic interventions.

The study, a descriptive cross-sectional analysis, involved 146 patients with RBDs who had sought medical attention at the hospital, with a mean age of 23.11 ± 14.6. The most common disorder observed among the patients was FVIII deficiency, accounting for 65.8% of cases, whereas the rarest disorder was FXIII deficiency, found in only 4.8% of cases.

The average survival time for any cause was 54.42 ± 1.3 months. Comparing the survival rates across different deficiencies, patients with combined FV and FVIII deficiencies exhibited a longer survival time (55.9 ± 5.7 months) than those with other deficiencies, although the difference was not statistically significant (P ≥ 0.05). Conversely, patients with FXIII deficiency had a lower survival rate (44 ± 9.6 months) than other cases, but this difference was also not statistically significant (P ≥ 0.05).

Reference
Jahangiri A, Ahmadi S, Rafieemehr H. Survival analysis of coagulation disorders: A retrospective study with a 5-year follow-up. Heliyon. 2023;9(6):e16376. doi: 10.1016/j.heliyon.2023.e16376. PMID: 37274668; PMCID: PMC10238680.